{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T10:32:57Z","timestamp":1789813977361,"version":"4.0.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"crossref","award":["GZ-2011-10753"],"award-info":[{"award-number":["GZ-2011-10753"]}],"id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.atherosclerosis.2017.02.019","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T03:30:12Z","timestamp":1487907012000},"page":"20-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study)"],"prefix":"10.1016","volume":"259","author":[{"given":"Elisa","family":"Waldmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Vogt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Crispin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Altenhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Riks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus G.","family":"Parhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2017.02.019_bib1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.atherosclerosis.2016.08.018","volume":"253","author":"Catapano","year":"2016","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2017.02.019_bib2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/MOL.0b013e32833e13fd","article-title":"Lipoprotein apheresis","volume":"21","author":"Thompson","year":"2010","journal-title":"Curr. Opin. Lipidol."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2017.02.019_bib3","first-page":"774","article-title":"PCSK9 inhibitors and cardiovascular events","volume":"373","author":"Sabatine","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2017.02.019_bib4","first-page":"774","article-title":"PCSK9 inhibitors and cardiovascular events","volume":"373","author":"Robinson","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"9719","key":"10.1016\/j.atherosclerosis.2017.02.019_bib5","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet (London, Engl."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2017.02.019_bib6","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/jca.10010","article-title":"The effects of three different LDL-apheresis methods on the plasma concentrations of E-selectin, VCAM-1, and ICAM-1","volume":"17","author":"Empen","year":"2002","journal-title":"J.\u00a0Clin. Apher."},{"issue":"7","key":"10.1016\/j.atherosclerosis.2017.02.019_bib7","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S0026-0495(98)90127-5","article-title":"Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia","volume":"47","author":"Richter","year":"1998","journal-title":"Metabolism Clin. Exp."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2017.02.019_bib8","doi-asserted-by":"crossref","first-page":"e49006","DOI":"10.1371\/journal.pone.0049006","article-title":"Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy","volume":"7","author":"McGowan","year":"2012","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2017.02.019_bib9","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1161\/ATVBAHA.114.304549","article-title":"Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials","volume":"35","author":"Santos","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"19","key":"10.1016\/j.atherosclerosis.2017.02.019_bib10","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1161\/CIRCULATIONAHA.112.104125","article-title":"Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease","volume":"126","author":"Stein","year":"2012","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.atherosclerosis.2017.02.019_bib11","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.111.042523","article-title":"Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy","volume":"124","author":"Raal","year":"2011","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2017.02.019_bib12","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/eurheartj\/eht549","article-title":"Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension","volume":"36","author":"Santos","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2017.02.019_bib13","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.atherosclerosissup.2015.02.028","article-title":"Effects of lipoprotein apheresis on PCSK9 levels","volume":"18","author":"Julius","year":"2015","journal-title":"Athersoclerosis Sup"},{"key":"10.1016\/j.atherosclerosis.2017.02.019_bib14","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/S0022-2275(20)31992-1","article-title":"Acute effects of low density lipoprotein apheresis on metabolic parameters of apolipoprotein B","volume":"41","author":"Parhofer","year":"2000","journal-title":"J.\u00a0Lipid Res."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2017.02.019_bib15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1046\/j.1365-2796.1999.00508.x","article-title":"Atherosclerosis seems not to be associated with hyperinsulinaemia in patients with familial hypercholesterolaemia","volume":"246","author":"Raal","year":"1999","journal-title":"J.\u00a0Intern. Med."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2017.02.019_bib16","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/eurheartj\/ehs023","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial","volume":"33","author":"Visser","year":"2012","journal-title":"Eur. Heart J."},{"issue":"9753","key":"10.1016\/j.atherosclerosis.2017.02.019_bib17","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials","volume":"376","year":"2010","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.atherosclerosis.2017.02.019_bib18","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"European atherosclerosis society consensus panel. Statin-associated muscle symptoms: impact on statin therapy\u2013european atherosclerosis society consensus panel statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2017.02.019_bib19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pcad.2016.07.006","article-title":"Familial hypercholesterolemia: advances in recognition and therapy","volume":"59","author":"Cartier","year":"2016","journal-title":"Prog. Cardiovasc Dis."},{"issue":"48","key":"10.1016\/j.atherosclerosis.2017.02.019_bib20","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1093\/eurheartj\/ehw388","article-title":"Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial","volume":"37","author":"Moriarty","year":"2016","journal-title":"Eur. Heart J."}],"updated-by":[{"DOI":"10.1016\/j.atherosclerosis.2018.05.020","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000}}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915017300710?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915017300710?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,24]],"date-time":"2022-07-24T14:41:47Z","timestamp":1658673707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915017300710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":20,"alternative-id":["S0021915017300710"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.02.019","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.atherosclerosis.2018.05.020","asserted-by":"object"}]},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study)","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.02.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}